Effect of non-genetic factors on paraoxonase 1 activity in patients undergoing hemodialysis

Clinical Biochemistry

Volumn 43, Issue 18, 2010, Pages 1375-1380

  Rajković, Marija Grdić ^a   Rumora, Lada ^a   Juretić, Dubravka ^a   Grubišić, Tihana Žanić ^a   Flegar Meštrić, Zlata ^b   Vrkić, Nada ^c   Sinjeri, Željko ^d   Barišić, Karmela ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b University of Zagreb   (Croatia)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^d Tomislav Bardek General Hospital   (Croatia)

Author keywords

Hemodialysis; High density lipoproteins; Oxidative stress; Paraoxonase 1

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CREATININE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; THIOL; UREA; URIC ACID;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME METABOLISM; FEMALE; HEMODIALYSIS PATIENT; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHENOTYPE; PRIORITY JOURNAL; ULTRAFILTRATION;

AGED; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CARDIOVASCULAR DISEASES; CREATININE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; RENAL DIALYSIS; SULFHYDRYL COMPOUNDS; UREA;

EID: 78149497677     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.08.024     Document Type: Article

References (44)

1. Draganov D.I., La Du B.N. Pharmacogenetics of paraoxonases: a brief review, Naunyn. Schmiedebergs. Arch Pharmacol 2004, 369:78-88.
2. Fuhrman B., Volkova N., Aviram M. Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis 2005, 180:55-61.
3. James R.W., Deakin S.P. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004, 37:1986-1994.
4. Ng C.J., Shih D.M., Hama S.Y., Villa N., Navab M., Reddy S.T. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005, 38:153-163.
5. Aviram M. Introduction to the serial review on paraoxonases, oxidative stress, and cardiovascular diseases. Free Radic Biol Med 2004, 37:1301-1303.
6. Yeung D.T., Josse D., Nicholson J.D., Khanal A., McAndrew C.W., Bahnson B.J., et al. Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model. Biochim Biophys Acta 2004, 1702:67-77.
7. Josse D., Xie W., Renault F., Rochu D., Schopfer L.M., Masson P., et al. Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. Biochemistry 1999, 38:2816-2825.
8. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998, 18:1617-1624.
9. Shoji T., Nishizawa Y. Plasma lipoprotein abnormalities in hemodialysis patients-clinical implications and therapeutic guidelines. Ther Apher Dial 2006, 10:305-315.
10. González Rico M., Puchades M.J., García Ramón R., Sáez G., Tormos M.C., Miguel A. Effect of hemodialysis therapy on oxidative stress in patients with chronic renal failure. Nefrologia 2006, 26:218-225.
11. Dantoine T.F., Debord J., Charmes J.P., Merle L., Marquet P., Lachatre G., et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998, 9:2082-2088.
12. Dronca M., Paşca S.P., Nemeş B., Vlase L., Vladutiu D. Serum paraoxonase 1 activities and homocysteinemia in hemodialysis patients. Clin Chem Lab Med 2008, 46:880-881.
13. Gugliucci A., Mehlhaff K., Kinugasa E., Ogata H., Hermo R., Schulze J., et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta 2007, 377:213-220.
14. Juretić D., Motejlkova A., Kunović B., Rekić B., Flegar-Meštrić Z., Vujić L., et al. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus. Acta Pharm 2006, 56:59-68.
15. Grdić M., Barišić K., Rumora L., Salamunić I., Tadijanović M., Žanić Grubišić T., et al. Genetic frequencies of paraoxonase 1 gene polymorphisms in Croatian population. Croat Chem Acta 2008, 81:105-111.
16. Reiner E., Svedružić D., Simeon-Rudolf V., Lipovac V., Gavella M., Mrzljak V. Paraoxonase and arylesterase activities in the serum of two hyperlipoproteinaemic patients after repeated extracorporal lipid precipitation. Chem Biol Interact 1999, 405-411. 119 - 120.
17. Eckerson H.W., Wyte C.M., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983, 35:1126-1138.
18. Hu M.L. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994, 233:380-385.
19. Drury J.A., Nycyk J.A., Cooke R.W.I. Comparison of urinary and plasma malondialdehyde in preterm infants. Clin Chim Acta 1997, 263:177-185.
20. Žlender V., Breljak D., Ljubojević M., Flajs D., Balen D., Brzica H., et al. Low doses of ochratoxin A upregulate the protein expression of organic anion transporters Oat1, Oat2, Oat3 and Oat5 in rat kidney cortex. Toxicol Appl Pharmacol 2009, 239:284-296.
21. Deakin S.P., James R.W. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci 2004, 107:435-447.
22. Juretić D., Tadijanović M., Rekić B., Simeon-Rudolf V., Reiner E., Baričić M. Serum paraoxonase activities in hemodialyzed uremic patients. cohort study Croat Med J 2001, 42:146-150.
23. Suehiro T., Ikeda Y., Shiinoki T., Inoue M., Kumon Y., Itahara T., et al. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 2002, 9:133-138.
24. Jurek A., Turyna B., Kubit P., Klein A. LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failure. Clin Biochem 2006, 39:19-27.
25. Ferretti G., Bacchetti T., Masciangelo S., Pallotta G. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 2008, 41:381-386.
26. Dircan M., Akça R., Sarandol E., Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 2004, 17:813-818.
27. Piperi C., Kalofoutis C., Tzivras M., Troupis T., Skenderis A., Kalofoutis A. Effects of hemodialysis on serum lipids and phospholipids of end-stage renal failure patients. Mol Cell Biochem 2004, 265:57-61.
28. Schiavon R., Battaglia P., De Fanti E., Fasolin A., Biasioli S., Targa L., et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002, 324:39-44.
29. Biasioli S., Schiavon R., Petrosino L., De Fanti E., Cavalcanti G., Battaglia P., et al. Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia. ASAIO J 2003, 49:295-299.
30. Nevin D.N., Zambon A., Furlong C.E., Richter R.J., Humbert R., Hokanson J.E., et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL, Arterioscler Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 1996, 16:1243-1249.
31. Hasselwander O., McMaster D., Fogarty D.G., Peter Maxwell A., Paul Nicholls D., Young I.S. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998, 44:179-181.
32. Vanholder R., Van Laecke S., Glorieux G. What is new in uremic toxicity?. Pediatr Nephrol 2008, 23:1211-1221.
33. Schiavon R., De Fanti E., Giavarina D., Biasioli S., Cavalcanti G., Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996, 247:71-80.
34. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000, 32:307-326.
35. Ward R.A., McLeish K.R. Oxidant stress in hemodialysis patients: what are the determining factors. Artif Organs 2003, 27:230-236.
36. Valentini J., Grotto D., Paniz C., Roehrs M., Burg G., Garcia S.C. The influence of the hemodialysis treatment time under oxidative stress biomarkers in chronic renal failure patients. Biomed Pharmacother 2008, 62:378-382.
37. Hewitson C.L., Whiting M.J., Barbara J.A., Mangoni A.A. Acute effects of haemodialysis on biochemical modulators of endothelial function. J Intern Med 2007, 262:571-580.
38. Moradi H., Pahl M.V., Elahimehr R., Vaziri N.D. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 2009, 153:77-85.
39. Jackson P., Loughrey C.M., Lightbody J.H., McNamee P.T., Young I.S. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 1995, 41:1135-1138.
40. Himmelfarb J., McMonagle E., McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000, 58:2571-2578.
41. Prakash M., Shetty J.K., Rao L., Sharma S., Rodrigues A., Prabhu R. Serum paraoxonase activity and protein thiols in chronic renal failure patients. Indian Journal of Nephrology 2008, 18:13-16.
42. Mallikarjunappa S., Prakash M. Urine protein thiols in chronic renal failure patients. Indian Journal of Nephrology 2007, 17:7-9.
43. Jaouad L., de Guise C., Berrougui H., Cloutier M., Isabelle M., Fulop T., et al. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups. Atherosclesrosis 2006, 185:191-200.
44. Sorenson R.C., Primo-Parmo S.L., Kuo C.L., Adkins S., Lockridge O., La Du B.N. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci 1995, 92:7187-7191.